Richard Pasternak to replace Jean-Pierre Garnier as chairman of Cerenis

3 September 2014
cerenis-big

French biotechnology company Cerenis has appointed Richard Pasternak as chairman of the board of directors. The current chairman, Jean-Pierre Garnier, a former chief executive of GlaxoSmithKline and France’s Pierre Fabre, is stepping down for personal reasons.

Dr Pasternak is an academic and biopharma clinician-scientist with 35 years’ experience and a research interest in vascular diseases, lipid disorders and atherosclerosis. He has served as a non-executive director on Cerenis’ board since November 2011.

He has previously held senior management positions at Merck & Co between 2004 and 2010, and before this was director of preventive cardiology and cardiac rehabilitation at Massachusetts General Hospital, and associate professor of medicine at Harvard Medical School.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight